Ryutaro is a Partner with Catalys Pacific. Previous to Catalys Pacific, he led R&D at Kyowa Kirin Co., Ltd. (previously known as Kyowa Hakko Kirin Co., Ltd.) as Executive Officer. During his tenure at the company as Global Head of Nephrology R&D, he led the development and regulatory filings of top-selling medicines including Darbepoetin alfa, Evocalcet, Pegfilgrastim, and Burosumab. Ryutaro has led over 10 product launches in Japan and East Asia. He brings deep experience with PMDA on regulatory strategy and the submission and approval of multiple pharmaceutical products.

He graduated from Tokyo University of Science and is a Qualified Pharmacist